# Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

> **NCT00378209** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 65 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00378209
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2012-10
- **Final completion:** 2016-10
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2016-11-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378209, "Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00378209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*